BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $67,254 | -21.4% | 988 | -5.7% | 0.00% | 0.0% |
Q2 2023 | $85,549 | +6.0% | 1,048 | -3.7% | 0.00% | 0.0% |
Q1 2023 | $80,720 | -10.5% | 1,088 | 0.0% | 0.00% | -33.3% |
Q4 2022 | $90,174 | +10.0% | 1,088 | +275.2% | 0.00% | 0.0% |
Q3 2022 | $82,000 | -18.0% | 290 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $100,000 | -20.0% | 290 | 0.0% | 0.00% | -25.0% |
Q1 2022 | $125,000 | -16.7% | 290 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $150,000 | +435.7% | 290 | +400.0% | 0.00% | +300.0% |
Q3 2021 | $28,000 | +7.7% | 58 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $26,000 | 0.0% | 58 | -14.7% | 0.00% | 0.0% |
Q1 2021 | $26,000 | +8.3% | 68 | -9.3% | 0.00% | 0.0% |
Q4 2020 | $24,000 | +26.3% | 75 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $19,000 | -9.5% | 75 | -3.8% | 0.00% | 0.0% |
Q2 2020 | $21,000 | +10.5% | 78 | -22.0% | 0.00% | 0.0% |
Q1 2020 | $19,000 | -13.6% | 100 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $22,000 | +10.0% | 100 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $20,000 | -4.8% | 100 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $21,000 | -12.5% | 100 | -16.7% | 0.00% | 0.0% |
Q1 2019 | $24,000 | -63.6% | 120 | -73.7% | 0.00% | -75.0% |
Q4 2018 | $66,000 | -92.3% | 457 | -89.1% | 0.00% | -92.0% |
Q3 2018 | $859,000 | +35.9% | 4,207 | -1.5% | 0.05% | +25.0% |
Q2 2018 | $632,000 | -2.0% | 4,272 | 0.0% | 0.04% | -2.4% |
Q1 2018 | $645,000 | +7962.5% | 4,272 | +4754.5% | 0.04% | +4000.0% |
Q3 2015 | $8,000 | -11.1% | 88 | 0.0% | 0.00% | 0.0% |
Q2 2015 | $9,000 | 0.0% | 88 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $9,000 | +12.5% | 88 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $8,000 | – | 88 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |